Residual gastric content and aspiration-related outcomes in perioperative patients treated with semaglutide: A systematic review and meta-analysis

Table 1 Baseline characteristics of patients in the included studies (reported data only) (total n = 49651), n (%)/mean ± SD

Variable	Semaglutide	Control
Patients	11022 (22.2)	38629 (77.8)
Sex (female)	2514 (45.5)	8785 (43.9)
Age (mean years)	56.7 ± 7.41	56 ± 8.95
BMI (mean)	31.58 ± 4.54	29.2 ± 3.28
ASA
I	69 (0.6)	313 (0.8)
II	214 (1.94)	1094 (2.8)
III	8 (0.07)	184 (0.4)
IV	0 (0)	1 (0.002)
V	0 (0)	0 (0)
Comorbidities
Type 2 diabetes	4631 (42.3)	15253 (40.8)
GERD	917 (8.3)	3313 (8.8)
Opioid use	1501 (13.7)	5712 (15.2)
Abdominal surgery	3	51
Cirrhosis	15	11
HbA1c (mean)	6.48 ± 0.58	6.42 ± 0.67
	47 mmol/mol	47 mmol/mol
Duration (mean day)	149 ± 127	-
Dose (mean mg)	1.33 ± 0.23	-
Fasting (mean hours)
Solids	12.89 ± 3.28	12.83 ± 3.27
Clear fluids	6.51 ± 3.14	7.66 ± 3.8

Values are based on available reported data. Not all studies reported every baseline variable; thus, denominators may differ between characteristics and from those used in the pooled effect-size calculations for specific outcomes (e.g., residual gastric content and aspiration). BMI: Body mass index; ASA: American Society of Anesthesiologists Physical Status classification; GERD: Gastroesophageal reflux disease; HbA1c: Glycated hemoglobin.